HK1201179A1 - Antacid tablet - Google Patents

Antacid tablet Download PDF

Info

Publication number
HK1201179A1
HK1201179A1 HK15101650.2A HK15101650A HK1201179A1 HK 1201179 A1 HK1201179 A1 HK 1201179A1 HK 15101650 A HK15101650 A HK 15101650A HK 1201179 A1 HK1201179 A1 HK 1201179A1
Authority
HK
Hong Kong
Prior art keywords
tablet
present
antacid tablet
tablets
hardness
Prior art date
Application number
HK15101650.2A
Other languages
English (en)
Chinese (zh)
Inventor
Maria S. Mirabile
Sandip G. Shah
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of HK1201179A1 publication Critical patent/HK1201179A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/10—Carbonates; Bicarbonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK15101650.2A 2012-02-02 2013-01-31 Antacid tablet HK1201179A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261594055P 2012-02-02 2012-02-02
US61/594,055 2012-02-02
PCT/US2013/024078 WO2013116477A1 (en) 2012-02-02 2013-01-31 Antacid tablet

Publications (1)

Publication Number Publication Date
HK1201179A1 true HK1201179A1 (en) 2015-08-28

Family

ID=48905820

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15101650.2A HK1201179A1 (en) 2012-02-02 2013-01-31 Antacid tablet

Country Status (12)

Country Link
US (1) US20140037759A1 (enExample)
EP (1) EP2809331A4 (enExample)
CN (1) CN104136033A (enExample)
AR (1) AR089857A1 (enExample)
BR (1) BR112014019155A8 (enExample)
CA (1) CA2863389A1 (enExample)
CO (1) CO7020922A2 (enExample)
HK (1) HK1201179A1 (enExample)
IN (1) IN2014DN06198A (enExample)
MX (1) MX2014009391A (enExample)
WO (1) WO2013116477A1 (enExample)
ZA (1) ZA201405354B (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025222289A1 (en) * 2024-04-23 2025-10-30 Biovantek Calcium carbonate formulations and method of treatment of gastroesophageal reflux disease (gerd)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU9202318D0 (en) * 1991-07-22 1992-10-28 Bristol Myers Squibb Co Method for preparing medical preparatives containing didesoxi-purine nucleoside
GB9825033D0 (en) * 1998-11-13 1999-01-13 Nycomed Pharma As Process
US6358526B1 (en) * 2000-08-16 2002-03-19 Rexall Sundown Method of making tablets and tablet compositions produced therefrom
JP2006516562A (ja) * 2003-01-24 2006-07-06 ステート オブ イスラエル、ミニストリー オブ アグリカルチャー 抗酸化活性を増強するための相乗的な組成物及び方法
CA2514875A1 (en) * 2003-02-19 2004-09-02 Biovail Laboratories International Srl Rapid absorption selective 5-ht agonist formulations
UA95093C2 (uk) * 2005-12-07 2011-07-11 Нікомед Фарма Ас Спосіб одержання кальцієвмісної сполуки
WO2007134158A2 (en) * 2006-05-12 2007-11-22 Drugtech Corporation Granules comprising calcium carbonate, a binder and a porosity increasing agent, processes of manufacturing, use in therapy

Also Published As

Publication number Publication date
AR089857A1 (es) 2014-09-24
CN104136033A (zh) 2014-11-05
CA2863389A1 (en) 2013-08-08
US20140037759A1 (en) 2014-02-06
EP2809331A4 (en) 2015-07-15
CO7020922A2 (es) 2014-08-11
BR112014019155A2 (enExample) 2017-06-20
IN2014DN06198A (enExample) 2015-10-23
WO2013116477A1 (en) 2013-08-08
BR112014019155A8 (pt) 2017-07-11
ZA201405354B (en) 2015-11-25
EP2809331A1 (en) 2014-12-10
MX2014009391A (es) 2014-08-27

Similar Documents

Publication Publication Date Title
ZA202202711B (en) Sustained-release dosage forms of ruxolitinib
MY159630A (en) Pharmaceutical composition comprising linagliptin and optionally a sglt2 inhibitor, and uses thereof
TN2009000093A1 (en) Pharmaceutical compositions comprising nilotinib or its salt
UA92641C2 (ru) Комбинированная препаративная форма, которая содержит амлодипин и лозартан
MX343358B (es) Tabletas de acetato de ulipristal.
UA92077C2 (uk) Таблетка, що диспергується у роті
PH12012502083A1 (en) Manufacturing of active-free granules and tablets comprising the same
MY157673A (en) Pharmaceutical compositions comprising hydromorphone and naloxone
PH12012502082A1 (en) Combination of active loaded granules with additional actives
WO2011090694A8 (en) Orally administrable film dosage forms containing ondansetron
TN2015000135A1 (en) Modified release formulations for oprozomib
WO2008129501A3 (en) Pharmaceutical compositions of duloxetine
MX2010001705A (es) Co-cristales de pirimetanilo y ditianona.
WO2011091410A8 (en) Trpv4 antagonists
CA2863389A1 (en) Antacid tablet
WO2009106960A3 (en) Stable compositions of lamivudine, tenofovir and efavirenz
WO2009060064A3 (en) Pharmaceutical formulations for the oral administration of ppi
EA201001108A1 (ru) Диспергируемые во рту таблетки, содержащие основание эсциталопрама, и способ их получения
IN2014MN01382A (enExample)
MX2012002209A (es) Formulaciones de liberacion controlada de compuestos de anabaseina y usos de los mismos.
WO2011161223A3 (en) Pharmaceutical oral dosage forms comprising lercanidipine and enalapril and their pharmaceutically acceptable salts
ATE525064T1 (de) Pharmazeutische zusammensetzung mit desloratadin
BR112013000870A2 (pt) forma de dosagem farmacêutica oral em comprimidos
WO2010084111A3 (en) Pharmaceutical composition of ibandronate sodium salt or a hydrate thereof
WO2006093786A3 (en) Scopolamine sublingual spray